Welcome to our dedicated page for Brainsway Ltd. news (Ticker: BWAY), a resource for investors and traders seeking the latest updates and insights on Brainsway Ltd. stock.
BrainsWay Ltd (BWAY) delivers innovative neurostimulation solutions through its FDA-cleared Deep TMS technology, offering noninvasive treatment for mental health disorders. This news hub provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and corporate developments.
Access timely information about earnings reports, research collaborations, and therapeutic applications of Deep TMS technology. Our curated collection features official press releases and verified news covering treatment efficacy studies, global expansion efforts, and strategic partnerships.
Discover updates on BrainsWay's progress in addressing major depressive disorder, OCD, and addiction treatment through its patented magnetic stimulation platform. The resource serves investors monitoring neurotechnology trends and clinicians seeking evidence-based therapeutic innovations.
Bookmark this page for structured access to BWAY's latest developments in neuromodulation science and mental health treatment advancements. Stay informed about breakthrough clinical data and operational updates from this leader in noninvasive brain stimulation solutions.
BrainsWay (NASDAQ & TASE: BWAY) reported strong financial results for Q4 and full year 2024. The company achieved record quarterly sales of $11.4 million in Q4 2024, up 27% from Q4 2023, and full-year revenue of $41 million, representing a 29% year-over-year increase.
Q4 highlights include shipping 75 Deep TMS™ systems (25% increase), maintaining a 75% gross margin, and achieving operating income of $0.4 million. Full-year 2024 showed operating income of $1.4 million, compared to a $5.0 million loss in 2023, with net income of $2.9 million.
The company secured a $20 million strategic equity financing from Valor Equity Partners and ended 2024 with $69.4 million in cash. For 2025, BrainsWay projects revenue between $49-51 million (20-24% growth) with operating income of 3-4% and Adjusted EBITDA of 11-12%.
BrainsWay (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced its upcoming virtual presentation at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference.
The presentation is scheduled for March 18, 2025, at 9:20 AM EST. Investors and interested parties can access the live webcast through the Events & News – Presentations section of BrainsWay's Investor Relations website. A replay of the presentation will remain available for 30 days after the broadcast. Individual meetings with management can be arranged through Oppenheimer & Co representatives.
BrainsWay (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced it will report its fourth quarter and full year 2024 financial results on March 11, 2025, before the U.S. financial markets open.
The company will also provide operational highlights during the announcement. A conference call and webcast will be held at 8:30 AM Eastern Time to discuss these results and provide a business update. The live broadcast will be available on the company's website and will remain accessible for replay for 30 days.
BrainsWay (NASDAQ & TASE: BWAY) announced positive pilot data from an independent Stanford University study evaluating an accelerated Deep Transcranial Magnetic Stimulation (TMS) protocol for alcohol use disorder (AUD) treatment. The study, comparing 5 patients treated with BrainsWay's H7-Coil against 39 patients receiving other treatments, showed significant improvements including:
- Lower heavy drinking days (3% vs 22%)
- Reduced regular drinking days (15% vs 28%)
- Lower relapse rates (60% vs 74%)
Following the publication, the NIH awarded $1.5 million to the research team to explore Deep TMS efficacy in treating substance use addictions. The technology is not yet FDA-cleared for AUD treatment.
BrainsWay (NASDAQ & TASE: BWAY) announced positive feasibility clinical data for their Deep TMS™ therapy in treating peripheral neuropathic pain. The double-blind, randomized crossover trial involved 17 patients who received either active Deep TMS or sham treatment for five days, followed by a nine-week washout period before switching treatments. Results demonstrated significant reduction in usual pain intensity compared to sham treatment, along with improvements in comorbid anxiety and depression symptoms. The study was published in the Neuromodulation journal, though Deep TMS is not currently FDA-cleared for neuropathic pain treatment.
BrainsWay reported strong Q3 2024 financial results with revenues of $10.5 million, representing a 26% year-over-year increase. The company achieved a gross margin of 74% and operating income of $0.3 million, compared to a loss in Q3 2023. Net income reached $0.7 million, with Adjusted EBITDA of $1.1 million. The company shipped 177 Deep TMS systems in the first nine months of 2024, up 12% from last year. Following a $20 million equity financing from Valor Equity Partners, BrainsWay raised its full-year 2024 revenue guidance to $40-41 million, projecting 25-29% growth over 2023, with expected operating income of 3-4% and Adjusted EBITDA of 10-11%.
BrainsWay (NASDAQ & TASE: BWAY), a global leader in noninvasive neurostimulation treatments for mental health disorders, has scheduled its third quarter 2024 financial results announcement for November 12, 2024, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss results and provide business updates. The call will be accessible via multiple dial-in numbers and will be available for replay on the company's website for 30 days.
BrainsWay (NASDAQ & TASE: BWAY), a leader in noninvasive neurostimulation treatments for mental health disorders, has announced the placement of 15 new Deep Transcranial Magnetic Stimulation (Deep TMS™) systems in Taiwan and South Korea. This expansion marks a significant step in the company's penetration of the East Asian market.
CEO Hadar Levy highlighted the strategic importance of these countries in BrainsWay's international growth strategy, noting that the new orders demonstrate the company's ongoing commercial success in the region. The BrainsWay team, along with their international distribution partners, is focused on expanding global access to their innovative Deep TMS platform for both patients and healthcare providers.
BrainsWay (NASDAQ & TASE: BWAY) has announced a US$20 million private placement with Valor Equity Partners. The deal includes issuing 2,103,745 American Depositary Shares (ADSs) at US$9.51 per ADS, a 20% premium over the 30-day VWAP, and warrants to purchase up to 1,500,000 additional ADSs. If fully exercised, the warrants could increase total proceeds to US$34.3 million.
Valor will gain board representation and BrainsWay will use the funds for strategic initiatives including expanding market awareness, enhancing data analysis capabilities, developing R&D roadmap, and expanding access to Deep TMS™ technology. The transaction is subject to shareholder approval and customary closing conditions.
BrainsWay (NASDAQ & TASE: BWAY), a leader in noninvasive neurostimulation treatments for mental health disorders, has announced a significant expansion on the U.S. East Coast. A large and growing enterprise network has placed an order for 14 new Deep TMS™ systems, following other recent multisystem orders. This expansion aligns with BrainsWay's strategic goal of fostering relationships with various mental health groups and networks to drive long-term profitable growth.
CEO Hadar Levy expressed satisfaction with the company's continued expansion and support for the growth of this large enterprise network. As of June 30, 2024, BrainsWay had an installed base of 1,215 Deep TMS systems, solidifying its position as a preferred choice for many mental health providers.
